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A Quantitative Process for Enhancing End
of Phase 2 Decisions
Tony SABIN, James MATCHAM, Sarah BRAY, Andrew COPAS, and Mahesh K. B. PARMAR
The objectives of the phase 2 stage in a drug development
program are to evaluate the safety and tolerability of dif-
ferent doses, select a promising dose range, and look for
early signs of activity. At the end of phase 2, a decision
to initiate phase 3 studies is made that involves the com-
mitment of considerable resources. This multifactorial
decision, generally made by balancing the current condi-
tion of a development organization’s portfolio, the future
cost of development, the competitive landscape, and the
expected safety and efficacy benefits of a new therapy,
needs to be a good one. In this article, we present a prac-
tical quantitative process that has been implemented for
drugs entering phase 2 at Amgen Ltd. to ensure a con-
sistent and explicit evidence-based approach is used to
contribute to decisions for new drug candidates. Broadly
following this process will also help statisticians increase
their strategic influence in drug development programs.
The process is illustrated using an example from the pan-
creatic cancer indication. Embedded within the process
is a predominantly Bayesian approach to predicting the
probability of efficacy success in a future (frequentist)
phase 3 program.
Key Words: Decision making; Pancreatic cancer; Probability of
success.
1. Introduction
The aim of clinical drug development decision mak-
ing is to stop the development of nonviable treatments
as soon as possible. This avoids administering patients
unsafe or ineffective medicines, mitigates the drug de-
velopment costs, and makes both resources and patients
available for the development of other potentially more
promising treatments. There are a number of decision
points within the clinical drug development process, the
key ones being the decision to go into humans for the first
time, the transition to phase 2 after gaining evidence of
biological activity, the decision to initiate phase 3 (herein
referred to as the end of phase 2 (EOP2) decision) after
completion of dose ranging and finding, the commitment
to file with regulatory bodies and commitment to launch
into the market. It is well documented that considerable
attrition of potential drug candidates occurs in late phase
development (Kola and Landis 2004; Arrowsmith 2011a;
DiMasi et al. 2012), with lack of efficacy being the main
reason for failing phase 3 (Paul et al 2010; Arrowsmith
2011a,b). This is not good for patients or drug devel-
opment companies. It results in companies incurring the
majority of the drug development costs, which in turn
translates to a higher cost of medicines. The oncology
therapeutic area is a particularly noteworthy example,
where success rates for transitioning from phase to phase
have been lower than other therapeutic areas, with suc-
cess rate in phase 3 arguably unacceptably low (Kola and
Landis 2004; Arrowsmith 2011a). This is due to several
factors, including but not limited to, the use of outcome
measures in phase 2with poor predictive value for the out-
come measure used in phase 3 for drug registration pur-
poses and possible differences between the patient popu-
lations used for the corresponding phase 2 and 3 studies.
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The EOP2 decision is influenced by a number of fac-
tors, including the current condition of a development
organizations portfolio, the future cost of development,
the competitive landscape, and the expected safety and
efficacy benefit of a new therapy. There is a pressing
need to develop and implement methodologies and pro-
cesses to enhance the EOP2 decision-making capabilities
within the industry. The EOP2 decision should involve
a quantitative assessment of the available evidence, and
statisticians with experience in systematic data reviews,
quantitative modeling and experimental design have a
fundamental role to play in this. In this article, we present
a quantitative process for enhancing EOP2 decisions that
has been implemented for drugs entering phase 2 at Am-
gen Ltd. which if followed could ensure a more consistent
and explicit evidence-based approach is used to make de-
cisions for new drug candidates. While many of the in-
dividual components of this process are not new from a
statistical sense, the process formulation will be a use-
ful guide to pharmaceutical statisticians. The process is
divided into two stages as follows.
Stage 1: Systematic Literature Review and Data
Abstraction
For any disease area under investigation, ideally prior
to starting phase 2, the process begins with a literature
review focused on addressing the following core set of
questions:
1. Has the definition of disease changed over time?
2. What are the important prognostic markers for
the targeted indication?
3. What is the expected absolute treatment effect
of the current standard of care, and other drugs
either marketed or in development, for both the
phase 2 and primary phase 3 outcome measures?
4. What are the observed treatment effects of other
drugs relative to the standard of care for both the
phase 2 and primary phase 3 outcome measures?
5. What is the impact of the important prognostic
factors on the ability to detect a treatment effect
relative to the standard of care in both the phase
2 and primary phase 3 outcome measures (i.e.,
is there a prognostic factor by relative treatment
effect interaction)?
6. Have the absolute and relative treatment effects
changed over time?
7. What are the most common side effects and their
expected incidence rate?
8. What are the relationships between the phase 2
and primary phase 3 outcome measures for indi-
vidual treatment groups and also for differences
between treatment groups?
9. Are these relationships likely to hold for drugs
with different modes of action?
10. What is the impact of previous treatments on the
relationships between the phase 2 and 3 outcome
measures?
The relevant data are then systematically abstracted
and meta-analytical techniques applied to answer these
questions. These results enhance the EOP2 decision by
facilitating an appropriate choice of phase 2 and 3 study
design and trial populations, the selection of phase 2 out-
come measures, a comparison of the new treatment over
currently available and potential future competitor thera-
pies, and providing prior information on the relationship
between the phase 2 and phase 3 outcome measures for
use in Stage 2. It is very important to follow good practice
guidelines when conducting systematic literature reviews
to ensure that appropriate historical trials are selected to
support the decision making process (Moher et al. 2009;
Higgins and Green 2011). The inappropriate inclusion or
exclusion of trials will have a direct effect on the quality
of decisions made.
Stage 2: A Statistical Model for Predicting the
Probability of Success in Phase 3
One of the most important factors in the EOP2 deci-
sion is the expected efficacy. In this stage, a Bayesian
model is implemented to evaluate the probability of
achieving the required statistical criteria for efficacy suc-
cess in a future phase 3 study. The model synthesizes the
relationships between phase 2 and phase 3 study outcome
measures (on the relative treatment difference scale), the
influence of prognostic factors on the relationship, the
treatment difference observed for the phase 2 outcome
measure in the phase 2 study, the prior opinion of key de-
cision makers for the treatment difference in the phase 2
outcome measure, and knowledge of the proposed phase
3 study design to predict the probability of success (PoS)
in a future phase 3 study analyzed using frequentist statis-
tical methods. Additionally, reasonable bounds of belief
for the PoS are generated by running the model prediction
incorporating a range of subjective prior opinions repre-
senting different attitudes of key decision makers for the
treatment difference in the phase 2 outcome measure.
The entire data package generated provides direct ev-
idence on the unmet need and expected clinical value of
the new treatment, and can also be used as inputs to deter-
mine the cost of development (e.g., through sample size
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calculations), the benefit-risk and economic value of a
new treatment. Also, by implementing the process for all
new drugs entering phase 2, we aim to ensure all projects
competing for funding are assessed in a similar way and
on an equal footing.
Broadly following the concepts highlighted in this ar-
ticle will enable statisticians to contribute greatly to many
aspects of the decision-making process, and therefore en-
sure that good development plans, decision points, and
criteria are in place, as well as enhancing their strategic
influence. We expect that clinical development leaders
will highly value statisticians who are able to make these
types of contributions.
Some theoretical work has already been published in
this area. O’Hagan, Stevens, and Campbell (2005) intro-
duced the concept of assurance; an unconditional prob-
ability that a trial will achieve a specific outcome based
on prior knowledge for the unknown true treatment ef-
fect. Stallard, Whitehead, and Cleall (2005) proposed an
approach in which the posterior probability that a future
frequentist phase 3 study will be successful is calculated
and used to inform the decision to initiate phase 3 at
the interim and final analyses of a phase 2 trial. Nixon
et al. (2009a) described a model to predict the six-month
American College of Rheumatology (ACR) response rate
based upon theACR response rate collected at earlier time
points, for trials in rheumatoid arthritis. In this article, the
modeling is performed within a treatment arm on the ab-
solute scale. Nixon et al. (2009b) presented a rheumatoid
arthritis drug development model (RADDM), which sim-
ulates proposed phase 2b and 3 trials based upon efficacy
evidence on the ACR response rate at the end of phase 2a,
evidence of efficacy from existing treatments and expert
opinion on three key safety markers. Bayesian clinical
trial simulation is then used to determine the assurances
of licensing approval at the end of phase 3. Hong and
Shi (2012) presented a method that uses predictive power
to predict the probability of success in a phase 3 out-
come measure (i.e., the overall survival (OS) log hazard
ratio) based on a different phase 2 outcome measure (the
progression-free survival (PFS) log hazard ratio). This
approach requires specification of a prior for the corre-
lation between the treatment difference for the phase 2
outcome measure and the treatment difference for the
phase 3 outcome measure.
In the following sections, we present the process to
enhance EOP2 decisions implemented in practice for all
disease areas at Amgen Ltd., provide a case study using
the pancreatic cancer indication to highlight the model-
ing performed to predict the PoS in phase 3, draw some
conclusions, and indicate some areas for future method-
ological development. The modeling approach adopted
in the example differs from the Hong and Shi (2012)
publication by its use of meta-regression techniques to
estimate the relationship between the primary phase 2
outcome measure (PFS log hazard ratio) and the different
primary phase 3 outcome measure (OS log hazard ratio).
2. A Quantitative Process for Enhancing
End of Phase 2 Decisions
Stage 1: Systematic Literature Review
and Data Abstraction
For any disease area under investigation, the process
begins (ideally prior to starting phase 2) with a literature
review focused on identifying published trials relevant to
addressing the 10 core questions highlighted in Section 1.
The relevant data are then systematically abstracted from
the published literature and synthesized using standard
meta-analytical techniques. The data abstraction process
can be repeated prior to the EOP2 meeting to ensure that
any new information is incorporated into the EOP2 de-
cision. Given a large part of the EOP2 decision revolves
around predicting the treatment difference in the phase 3
study from the treatment difference observed in the phase
2, for the remainder of this section we focus on core ques-
tions 8–10, and the development of a statistical (usually
meta-regression)model to relate the treatment differences
seen with the phase 2 outcome measure to treatment dif-
ferences seen with the phase 3 outcome measure. This
relationship forms part of the prior knowledge required
for the statistical model for predicting the probability of
success in phase 3 described in stage 2.
In many situations where the phase 2 and phase 3 out-
come measures are different, for example, phase 2 stud-
ies may use short-term intermediate outcome measures,
rather than the longer-term outcome measures needed
for regulatory approval, using meta-regression to investi-
gate their relationship provides an understanding of how
good the outcome measure selected for phase 2 may be
at predicting the phase 3 outcome measure. Determin-
ing this relationship, from completed studies where both
the phase 2 and phase 3 outcome measures have been
collected, on the relative treatment effect scale is partic-
ularly valuable. This enables the development of a model
for estimating phase 3 outcomemeasure differences from
any given fixed value for the phase 2 outcome measure
difference. For example, assuming the relationship is lin-
ear and passes through the origin, the model to be fitted
is
μi = βZi , (1)
where μi is the true phase 3 outcome measure treatment
difference in the ith study, zi is the phase 2 outcome
measure treatment difference, considered as a fixed effect
at this stage, in the ith study, and β is the slope of the
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regression line. It should also be noted that the functional
form of the model does not have to be linear or forced
through the origin. Aswith anymodel it is simply amatter
of choosing a functional form that makes sense. If the
treatment differences are believed to be dependent upon
certain important prognostic characteristics of the studies
included in the meta-analysis, the above model may be
further expanded to include the prognostic characteristics
as trial level covariates.
The meta-data consist of study estimates of phase
3 outcome measure treatment differences, ϑˆi , with vari-
ance ε2i . To use a random effects model we assume ϑˆi is
normally distributed with mean μi , such that
ϑˆi ∼ N
(
μi , ε
2
i
)
and that μi is itself a realization of a normally distributed
random variable such that
μi ∼ N (ϕi , τ 2).
In our application of this method, we take a Bayesian
approach where β and τ are considered as hyperparame-
ters with independent prior distributions. A noninforma-
tive prior N(0,104) is given to β. Lambert et al. (2005)
and Spiegelhalter, Abrams, andMyles (2004) highlighted
the importance of carefully selecting the prior for τ . The
choice of prior for τ should bemade following a review of
the data, and sensitivity analyses conducted using a range
of realistic vague prior distributions. For the pancreatic
cancer example described later, we selected a uniform
(0,2) prior. The posterior distributions for β and τ can be
approximated usingMarkov chainMonte Carlo (MCMC)
methods.
Here, we also assume that the relationship between
the phase 2 and phase 3 outcome measures, determined
from the systematic review, will apply to the new drug
being tested. We recommend that sensitivity analyses are
performed to assess how robust predictions are for de-
partures from this relationship. This may be particularly
important when the new drug has a different mode of
action to many of the previous treatments. Alternatively,
if data permit, the relationship may be determined from
studies on treatments with similar modes of action.
Stage 2: A Statistical Model for Predicting
the PoS in Phase 3
A general overview of the statistical model used to es-
timate the PoS of the compound is provided in Figure 1.
The model synthesizes the relationships between phase
2 and phase 3 study outcome measures (on the relative
treatment difference scale), the influence of prognostic
Figure 1. Statistical model for predicting the probability of success in phase 3. Ph: Phase; trt: treatment; RCT: Randomized Controlled Trial; PoS:
probability of success.
70
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 C
oll
eg
e L
on
do
n]
 at
 07
:14
 21
 M
ay
 20
14
 
A Quantitative Process for Enhancing End of Phase 2 Decisions
factors on the relationship, the treatment difference ob-
served for the phase 2 outcome measure in the phase 2
study (prior to starting phase 2, simulated results may be
used to optimize the phase 2 design), a range of prior
opinions of key decision makers for the treatment differ-
ence in the phase 2 outcome measure, and knowledge of
the proposed phase 3 study design to predict the proba-
bility of success in a future phase 3 study analyzed using
frequentist statistical methods. The definition of success
may differ depending upon the objectives of the phase 3
study. In general, this is likely to be the probability of
achieving a favorable statistically significant efficacy re-
sult from an appropriate statistical test designed to reject,
or not the null-hypothesis of no difference between treat-
ments, on the primary Phase 3 outcome measure at the
conventional 5% two-sided level of significance.
The model uses a predominantly Bayesian approach
to what is a prediction problem, which we divide into four
steps.
Step 1. Ideally the first step would begin prior to start-
ing phase 2 where a range of plausible treatment
differences for the phase 2 outcome measure in
the planned phase 2 study is simulated. Each of
these simulationsmay in turn be used to evaluate
the PoS for the planned phase 3 study. Repeat-
ing this process using different options for the
phase 2 and 3 designs can help optimize the de-
velopment strategy for a specific indication. It
may be more usual that the process begins after
the phase 2 has already started or even com-
pleted. In either case, we assume the observed
(or simulated) treatment difference in the phase
2 outcome measure may be expressed as
d ∼ N (δ, σ 2d ). (2)
Step 2. A range of prior statistical distributions for
the phase 2 outcome measure treatment differ-
ence reflecting differing opinions of key deci-
sion makers is elicited. These priors enable us
to develop reasonable bounds of evidence in
Step 3 for the PoS in phase 3. These are cho-
sen to represent a noninformative prior distri-
bution δ ∼ N (δn, σ 2n ), an optimistic opinion for
the phase 2 treatment difference δ ∼ N (δ0, σ 20 ),
and a skeptical opinion δ ∼ N (δs, σ 2s ) (Spiegel-
halter, Freedman, and Palmer 1993). Taking the
prior belief of key decision makers into account
was an important component in the successful
implementation of this framework. In addition
to using the observed evidence, the ability to
make statements at the end of phase 2 meeting
that the PoS in phase 3 is still above a certain
value taking the point of view of themost skepti-
cal decision maker, or that the PoS is still below
a certain value taking into account the view of
the optimist decision maker brings valuable per-
spective to the go/no-go discussions. These pri-
ors are combined with the results from Equation
(2) to obtain a range of posterior statistical dis-
tributions for the treatment difference in terms
of the phase 2 outcome measure
p(δ |d ) = N
⎡
⎣δ
δ j
σ 2j
+ d
σ 2d
1
σ 2j
+ 1
σ 2d
,
1
1
σ 2j
+ 1
σ 2d
⎤
⎦ , (3)
where j = n, o, s.
Step 3. We now use the distribution of our expected
phase 2 outcome measure treatment differences
(Equation (3)), and the relationship between the
treatment differences for phase 2 and phase
3 outcome measures determined using meta-
regression from the systematic review (Equa-
tion (1)) to form distributions for the phase 3
outcome measure treatment difference. In our
Bayesian approach, we use the three different
prior distributions for the phase 2 treatment dif-
ference (representing skeptical, optimistic, and
noninformative opinions of key decision mak-
ers) to form three different predictive distribu-
tions for the phase 3 outcomemeasure treatment
difference. If the relative treatment differences
are believed to be dependent upon certain im-
portant prognostic characteristics of the studies
included in the meta-analysis, the model for the
relationship should include the prognostic char-
acteristics as trial level covariates. The predic-
tive distributions of the phase 3 outcome mea-
sure treatment difference may then be estimated
from the relationship by predicting the response
for the planned characteristics of the phase 3
study.
Recall that the model for the relationship
(Equation (1)) assumed Zi represents a fixed
value of the phase 2 outcome measure treatment
difference. During this step, the model is ex-
tended to ensure the uncertainty in the phase 2
outcome measure treatment difference in incor-
porated into the estimation of the posterior dis-
tributions of the phase 3 outcome measure. This
is done within the MCMC simulation by assum-
ing the phase 2 outcome measure treatment dif-
ference (Equation (3)) is a normally distributed
random variable.
Step 4. The range of predictive distributions for the
phase 3 outcome measure treatment differences
is used to simulate the results of the proposed
71
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phase 3 study design and estimate the PoS for
the future frequentist phase 3 study. The ear-
lier inclusion of skeptical and optimistic priors
leads to the development of reasonable bounds
of belief for the PoS.
The phase 3 study design parameters considered in-
clude the required level of statistical significance, the
desired size of the treatment difference, variance, and
the trial sample size. The PoS may be determined by
again using MCMC simulation. Assuming the predic-
tive distributions for the phase 3 outcome measure treat-
ment differences found in Step 3 are normally distributed
d3 ∼ N (μ, σ 22 ), and the future phase 3 data are normally
distributed X3 ∼ N (d3, σ 23 ):
1. Sample a value for the phase 3 treatment differ-
ence, d3(n) from the posterior distribution in Step
4.
2. Sample a value x (n)
3
given x (n)
3
.
3. Calculate the confidence interval for x (n)
3
and de-
termine whether this represents a favorable statis-
tically significant result.
4. Repeat n times and determine the proportion of
statistically significant outcomes.
Alternatively the PoS may be approximated as de-
scribed in Spiegelhalter, Abrams, and Myles (2004).
Rewriting σ 22 as
σ 2
n2
and σ 23 as
σ 2
n3
, the PoS for the hy-
pothesis x < 0 may be approximated by
φ
{√
n2
n2 + n3
(
μ
√
n3
σ
+ zα/2
)}
,
where φ denotes the cumulative standard normal distri-
bution. In addition to simulating the PoS, this approach
can be extended to simulate the probability of observing
a particular outcome in the phase 3 trial, that is, the prob-
ability P(x3 > y) that the phase 3 treatment difference is
greater than a selected value of interest y.
3. Worked Example: Predicting the PoS
in Pancreatic Cancer
We present a worked example of predicting the prob-
ability of success in pancreatic cancer. The example
implicitly shows where a project statistician was instru-
mental in working with their project team and other key
decision makers in the organization to understand the
phase 2 results in the light of the EOP2 decision about to
be made. Gemcitabine is indicated for use in the first-line
treatment of advanced pancreatic cancer and is the most
commonly used treatment in this setting. Here, we assume
that it is being used as the control group for a randomized
phase 2 study and is planned to be used for a future phase
3 study. The primary outcome measure being used in the
phase 2 study is PFS, a short-term outcome measure for
the phase 3 regulatory outcome measure, OS. The EOP2
decision is based upon treatment differences expressed in
terms of hazard ratios. We focus on predicting the distri-
bution for the OS hazard ratio in a planned phase 3 study
from the distribution of the PFS hazard ratio observed in
phase 2. The modeling is performed on the log hazard
ratio scale to allow the use of the normal distribution and
is transposed back onto the hazard ratio scale for presen-
tation purposes. The presence of metastases and ECOG
performance status are both considered to be prognostic
factors for OS. The phase 2 study is being conducted
in a 100% metastatic patient population with an ECOG
performance status of 0 or 1 at randomization. In this
example, the PoS in a future phase 3 study reflects the
probability of rejecting the null hypothesis that the log
OS hazard ratio (HR) = 0 (in favor of the experimental
treatment) at a two-sided 5% level of significance.
A thorough systematic literature review was con-
ducted to identify all published randomized trials over
the period from 2000 to 2012 in which gemcitabine was
used alone or in combination with other therapies. Details
of the selection criteria and chosen publications can be
found in the supplementary materials. In total, 43 stud-
ies were selected for detailed analysis. The methods in
Tierney et al. (2007) were used to estimate the median
survival, hazard ratio, and their associated standard errors
for the PFS and OS outcome measures. Data that were
relevant to predicting the gemcitabine control group PFS
andOS, the relationship betweenmedian PFS andmedian
OS, the relationship between the PFS hazard ratio and the
OS hazard ratio, and the pattern of treatment differences
seen with important study level covariates were synthe-
sized. Key learnings from this step pertinent to predicting
the PoS included:
• There is a strong association between the PFS haz-
ard ratio and the OS hazard ratio (Figure 2).
• Plots of the PFS hazard ratio and OS hazard ratio
against the study level characteristics percentage of
metastatic subjects, and percentage of ECOG 0/1
subjects showed there to be a wide range of val-
ues for the percentage of metastatic subjects, and
percentage of subjects with ECOG = 0/1, where
positive treatment effects have been shown. More-
over, there is no range of values where a treatment
effect has not been shown, and no evidence of as-
sociation between these study-level covariates and
outcome.
72
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 C
oll
eg
e L
on
do
n]
 at
 07
:14
 21
 M
ay
 20
14
 
A Quantitative Process for Enhancing End of Phase 2 Decisions
Figure 2. Random effects meta-regression for OS hazard ratio from PFS hazard ratio. Axes are back transposed from a linear regression between
OS log(HR) and PFS log(HR), The diameter of the circles is inversely proportional to the SE of the OS log(HR) for each published study. Plot
shows the predicted mean and 95% CI of a new study for fixed PFS hazard ratios.
Step 1. Table 1 presents an example assuming that the
PFS HR observed in phase 2 is 0.8 (log PFS HR
= −0.223, with variance 0.05). This represents
a phase 2 study comparing a new treatment with
gemcitabine analyzed after 80 subjects have ex-
perienced a PFS event.
Step 2. Three prior distributions for the log PFS
hazard ratio were elicited from key decision
makers to represent noninformativeN (0, 102),
skeptical N (0, 0.21682), and optimistic
N (−0.357, 0.34412) prior opinions. The skep-
tical distribution reflects the opinion that the
new treatment shows on average no benefit in
PFS time relative to gemcitabine, but there is a
5% chance that the new treatment is better than
gemcitabine with a hazard ratio ≤0.70. The
optimistic distribution represents an average a
hazard ratio of 0.70, with a 15% chance that the
new treatment is no better than control, that is,
a hazard ratio ≥ 1. Each of these distributions
is then combined with the observed phase 2
results to obtain a range of posterior estimates
for the PFS log HR (Table 1).
Step 3. The relationship between the PFS hazard ratio
and OS hazard ratio using the systematically ab-
stracted data was investigated using Bayesian
meta-regression (Figure 2). Each point in Fig-
ure 2 represents the results of one completed
study, from which both the PFS hazard ratio and
corresponding OS hazard ratio were abstracted.
In this example, we apply a no-intercept model
forcing the regression through the origin. The
Table 1. Estimating the probability of success with a phase 2 PFS result (HR = 0.8)
Skeptical Noninformative Optimistic
Mean SE Mean SE Mean SE
Prior PFS log HR 0 0.217 0 10 −0.357 0.344
Observed Ph 2 PFS log HR −0.223 0.224 −0.223 0.224 −0.223 0.224
Posterior PFS log HR −0.108 0.155 −0.224 0.223 −0.264 0.189
Predicted Ph 2 OS log HR −0.072 0.109 −0.151 0.155 −0.183 0.135
Probability of Ph 3 success 0.19 0.39 0.46
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potential for publication bias was minimized by
including all randomized phase 2 and 3 studies
in the model. Sensitivity analysis excluding the
small earlier phase studies from the analysis was
conducted and showed the small studies to have
little impact on the parameter estimates. Also,
given no evidence of association between the
percentage of metastatic patients or percentage
of ECOG0/1 patients, and the PFS logHR orOS
log HRwas observed, the selected model did not
include these factors as study-level covariates.
Each of the posterior distributions for the phase
2 outcome measure (PFS log HR) is synthesized
with the meta-regression to estimate the predic-
tive distribution for the phase 3 outcome mea-
sure treatment difference, that is, the OS log HR
(Table 1). Within this step, the meta-regression
shown in Figure 2 is extended to ensure the un-
certainty in the phase 2 outcome measure, PFS
log HR, is incorporated. An example including
the noninformative prior is shown in Figure 3,
which shows the posterior predicted OS HR, as-
suming the PFS HR from a phase 2 study to be
analyzed after 80 PFS events are observed is at
this stage unknown.
Step 4. In this example, we assume the sample size for
the frequentist phase 3 study requires 380 deaths
to enable 80% power to detect an OS hazard of
0.75 or less with a statistical significance level
of 0.05 (5%). In this step, the predictive distri-
butions for the log OS HR calculated in Step
3 are used to simulate the results of the pro-
posed phase 3 study design, which in turn can
be used to determine the probability of differ-
ent patterns of study results, including the PoS.
Table 1 completes the example determining the
PoS for the planned phase 3 study assuming an
observed phase 2 PFS hazard ratio of 0.8. The
skeptical and optimistic priors can be viewed as
providing reasonable bounds of belief for the es-
timated PoS. Assuming we observe a PFS HR=
0.8 in our phase 2 study we can conclude a PoS
in phase 3 ranging from 19% to 46% depending
on the prior belief. Figure 4 expands on the ex-
ample to show the estimated PoS across a range
of potentially observed phase 2 PFS hazard ra-
tios and prior distributions. It can be seen that
a PoS of at least 60% in phase 3 would require
the phase 2 PFS hazard ratio to be 0.7 or lower,
with a noninformative or optimistic prior belief.
Figure 3. Posterior predicted OS hazard ratio with a noninformative prior. Axes are back transposed from a linear regression between OS log(HR)
and PFS log(HR). The diameter of the circles is inversely proportional to the SE of the OS log(HR). Plot shows the OS HR posterior predicted mean
and 95% CrI assuming a phase 2 study with 80 observed PFS events and a noninformative prior for the PFS log HR.
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Figure 4. Probability of success in a phase 3 study Analyzed after 380 deaths.
Note, the lines for optimistic and uninformative
prior will naturally cross at the point where the
observed phase 2 results becomemore favorable
than the optimistic prior.
4. Discussion
The quantitative process for enhancing EOP2 deci-
sions presented in this article is designed to ensure a
consistent and explicit evidence-based approach is used
to inform decisions for new drug candidates. This re-
quires the systematic abstraction of data to support the
choice of phase 2 and 3 study design and population,
the appropriate selection of phase 2 outcome measures, a
comparison of the new treatment over currently available
and potential future competitor therapies, and evaluation
of the probability of achieving the required statistical cri-
teria for efficacy success in a future phase 3 study. The
process results in a data package that provides direct ev-
idence on the unmet need and expected clinical value of
the new treatment, and can also be used as inputs to deter-
mine the cost of development, risk-benefit, and economic
value of a new treatment. It therefore contributes widely
to the value assessment undertaken at the EOP2. Evaluat-
ing the probability of efficacy success in phase 3 using the
methodology outlined in this article requires the relation-
ship between treatment differences seen using the phase
2 study outcome measure and treatment differences seen
using the phase 3 outcome measure to be developed from
prior studies. It also requires knowledge of how prognos-
tic factors could influence the treatment difference. The
process emphasizes the need to target a treatment differ-
ence in phase 3 that is clinically worthwhile, realistic,
and cost effective. The probability of success implicitly
assumes that this has been done.
By broadly following the concepts highlighted in this
article, statisticians can contribute greatly to project strat-
egy and the decision making process. In many ways, the
structure and process presented herein are just making ex-
plicit many of the implicit assumptions and decisions that
are made when deciding whether to move on from a phase
2 result to a phase 3 trial. Additionally, as highlighted in
the publication by Sargent et al. (2005), if convincing ev-
idence of a strong relationship between a short-term out-
come measure and the currently used phase 3 outcome
measure is found, there is potential to validate the use of
the phase 2 outcome measure as a surrogate for the phase
3 outcome measure, and therefore influence current prac-
tice. This may subsequently translate into reduced drug
development times.
Operationally, following such an approach is getting
easier over time. With study results now registered on
www.clinicaltrials.gov, more complete data are available
for meta-analyses which should translate to more robust
analyses. Additionally, access to the necessary software is
improving. Pharmaceutical statisticians may wish to take
note that the introduction of PROC MCMC means that
all of theMCMC-based analyses shown in this article can
now be easily conducted in SAS R©.
5. Future Work
In this article, we have presented a statistical model
for enhancing decisions based on predictions of treat-
ment differences for phase 3 outcome measures and
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using these to simulate specific trial designs to assess
the probability of phase 3 success. We have intentionally
not specified a probability of phase 3 success that should
be achieved to make a “go-to-phase 3” decision. The se-
lection of a benchmark for this PoS will be specific to
a funder/sponsor and their current portfolio, or could be
chosen relative to the reported industry averages for be-
ing successful in phase 3. For example, in oncology the
percentage of successful phase 3 studies for new treat-
ments has been reported to be as low as 40% (Kola and
Landis 2004) so predicted PoS lower than 40% would be
aiming at a “lower than industry average” chance of being
successful.
Our approach could also help to decide among differ-
ent development strategies for a specific indication. For
example, strategy A could be to conduct a small phase 2
study and begin a phase 3 study but with an early futility
analysis. Strategy B could be to conduct an interim analy-
sis within a phase 2 studywith a possible decision to begin
the phase 3 study immediately, or wait until completion
of the phase 2 study to decide on beginning a phase 3
study. Using the process in this article to produce phase 3
predictions and EOP2 decisions in simulations for thera-
pies that have a range of efficacy could be used to decide
the best strategy. This would entail finding the operat-
ing characteristics of the decision rule including the false
positive and false negative rates. In some instances, it may
be that only minimal phase 2 evidence will be enough to
make an adequate decision, whereas other instances may
require much larger phase 2 studies. In our approach, we
have considered the size of the phase 3 study to be fixed
at the size required to show a frequentist success (e.g., for
a superiority study with α = 0.05) and look at the PoS
for this study for a range of results for a fixed size phase
2 study. Another approach could be to fix the PoS for the
phase 3 study (at say 65%) and determine the size of the
phase 2 study required to achieve this for a range of phase
2 results. This could indicate how reliant a good EOP2
decision could be on the size of the phase 2 study.
Following regulatory approval of a new treatment,
it is important to gain agreement for reimbursement in
many different geographical regions. This may require
a form of Health Technology Appraisal to take place
which usually necessitates the use of indirect treatment
comparisons between treatments not already compared
in head-to-head trials. It would be valuable to extend
the methods outlined in this article to produce an early
prediction of the outcomes of these indirect comparison
analyses using the predictions of phase 3 outcomes at
the end of phase 2. As well as likely phase 3 efficacy
outcomes, the competitor situation is also an element
of EOP2 decision making and these types of analyses
could be used to quantify not only the magnitude of the
indirect treatment comparisons, but also their levels of
uncertainty at the phase 2 stage of the development. This
is likely to include analyses of outcome measures other
than phase 3 outcome measures that are important to
assessing the comparative value of treatments.
Additional work exploring approaches to synthesize a
prior for the control group response with the control arm
in the phase 2 study may be useful. The approach used in
the pancreatic cancer example takes the view that the ob-
served treatment difference is the best unbiased estimate
available and uses the control prior simply as an external
assessment of the trials robustness. An alternative could
be to assume that the control arms from the studies se-
lected in the systematic review are compatible with the
new phase 2 study control group data. Then assuming the
phase 2 study is comparative, a posterior expected treat-
ment difference in the phase 2 outcome measure calcu-
lated after initially combining the prior and phase 2 study
control results together. If the phase 2 is randomized, such
an approach would however break the randomization and
potentially introduce bias. However, this approach may
help to discount early optimistic phase 2 results (Kirby
et al. 2012). Additionally, our pancreatic model assumes
that the baseline hazard survivor function is consistent
across studies. While this may be a reasonable assump-
tion for a model that uses the relative treatment effects
from randomized trials, incorporating methods to adjust
for differences in the baseline hazard would be an impor-
tant attribute to develop for an approach that combines
the absolute treatment effects of trial arms across different
studies.
The pancreatic model assumes proportional hazards
within each study. While we do not have reason to doubt
this assumption in this indication, a potentially beneficial
alternative but more resource intensive approach would
be to use methods of data abstraction that reproduce the
individual patient data (Guyot et al. 2012). This would
facilitate selection of an appropriate model from a wide
set of parametric survival distributions. It would also al-
low for estimates of the difference in mean survival be-
tween treatments to be generated for use in cost effective-
ness analysis without the need for the proportional hazard
assumption.
The model has focused on the methods for enhancing
decision-making at the EOP2 with respect to the likely
efficacy of a new treatment. With some adjustment, the
general approach used in this article could be applied
to the evaluation of comparative safety data. This would
require investigating the relationships between phase 2
and phase 3 safety outcome measures to predict phase
3 safety outcomes given the results of phase 2 safety
assessment. If prediction of the likely efficacy and safety
outcomes for a phase 3 study can be achieved, then it
may also be possible to investigate the benefit-risk of a
new drug by employing one of the Benefit-Risk methods
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that are currently being identified (EMA Benefit-Risk
Methodology Project, 2011).
In conclusion, this article has outlined the process
that has been implemented for drugs entering phase 2 at
Amgen Ltd. designed to ensure a consistent and explicit
evidence-based approach is used to contribute to EOP2
decisions for newdrug candidates. It also provides a struc-
tured approach for collecting and synthesizing prior data
with the phase 2 data for a new treatment to predict out-
comes in future phase 3 studies. In thisway, the statistician
can enhance the subsequent EOP2 decision making for
the funder/sponsor.
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